Persistent COVID-19 symptoms in a community study of 606,434 people in England

Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n  ...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Nature communications Ročník 13; číslo 1; s. 1957 - 10
Hlavní autori: Whitaker, Matthew, Elliott, Joshua, Chadeau-Hyam, Marc, Riley, Steven, Darzi, Ara, Cooke, Graham, Ward, Helen, Elliott, Paul
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 12.04.2022
Nature Publishing Group
Nature Portfolio
Predmet:
ISSN:2041-1723, 2041-1723
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Long COVID remains a broadly defined syndrome, with estimates of prevalence and duration varying widely. We use data from rounds 3–5 of the REACT-2 study ( n   =  508,707; September 2020 – February 2021), a representative community survey of adults in England, and replication data from round 6 ( n   =  97,717; May 2021) to estimate the prevalence and identify predictors of persistent symptoms lasting 12 weeks or more; and unsupervised learning to cluster individuals by reported symptoms. At 12 weeks in rounds 3–5, 37.7% experienced at least one symptom, falling to 21.6% in round 6. Female sex, increasing age, obesity, smoking, vaping, hospitalisation with COVID-19, deprivation, and being a healthcare worker are associated with higher probability of persistent symptoms in rounds 3–5, and Asian ethnicity with lower probability. Clustering analysis identifies a subset of participants with predominantly respiratory symptoms. Managing the long-term sequelae of COVID-19 will remain a major challenge for affected individuals and their families and for health services. This study characterises Long COVID using data from the REACT-2 community-based study in England. It estimates that 38% (in autumn/winter 2020/21) and 22% (in spring 2021) of people reported at least one symptom 12 weeks after symptom onset; identifies risk factors for persistent symptoms; and finds evidence of symptom clustering.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-022-29521-z